StreetAlpha.app
Home › Stocks › RNTX

Rein Therapeutics, Inc. (RNTX)

Healthcare
$0.34
▼ −8.38%
LAST CLOSE · NOV 20

Rein Therapeutics develops inhaled drug candidates for rare lung diseases, led by a treatment for idiopathic pulmonary fibrosis. It last closed at $0.34 on Nov 20, down 8.38% on the day. For the quarter ended Sep 2026, RNTX reported EPS of -$0.06 on revenue of $0. Over its last 5 reports the stock moved an average of 8.3% the session after earnings. Over the last 12 months RNTX insiders bought $75K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is RNTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RNTX.

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$49.7M
EPS (diluted)
−$1.51
Valuation
Market cap
$29.1M
86.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$943K
At Sep 30
Shareholder equity
$52.8M
Shares outstanding
86.3M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From RNTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
May 15
2025 · next date not set yet
Reported EPS
-$0.06
Quarter ended Sep 2026
Year ago EPS
-$0.21
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$2.20Dec '24Mar 2025: -$0.25Mar '25Jun 2025: -$0.28Jun '25Sep 2025: -$0.21Sep '25Dec 2025: -$1.22Dec '25Mar 2026: -$0.19Mar '26Jun 2026: -$0.10Jun '26Sep 2026: -$0.06Sep '26Latest -$0.06
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How RNTX moved after its last 5 reports
Average move the session after a report ±8.3%
May 15, 2025After the close−6.4%
Nov 14, 2024After the close−13.3%
Aug 14, 2024After the close−10.8%
May 15, 2024After the close−1.3%
Apr 15, 2024After the close−9.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RNTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RNTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RNTX

Technical Analysis

RNTX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 68% below its 20 day and 97% below its 50 day average. It is 191% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot S1 at $0.32, and the nearest resistance the Pivot at $0.35.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 22.3%/day
Key levels
$2.1052 week high+517.6%
$0.98200 day average+188.2%
$0.75100 day average+120.6%
$0.6650 day average+94.1%
$0.65Swing high (Oct 21)+91.2%
$0.5720 day average+67.6%
$0.37Pivot R1+8.8%
$0.35Pivot+2.9%
$0.34Last close
$0.32Pivot S1−5.9%
$0.2852 week low−17.6%
$0.28Swing low (Nov 16)−17.6%
Indicators
RSI (14)24.71Oversold below 30Oversold
MACD-0.09Below its signal lineBearish
Stochastic15.5Near the bottom of its rangeOversold
ADX (14)31.6Trending down
Williams %R-88.2Oversold below −80, overbought above −20Oversold
CCI (20)-140.5Oversold below −100, overbought above 100Oversold
Rate of change−45.1%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 22.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RNTX

What happened before

See how RNTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RNTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RNTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RNTXHow many large options trades hit RNTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

RNTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲24 buying vs 16 selling
  • ●Held by funds +0.3 pts
  • ▲Funds holding +4
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6460+6.7%
In funds' top 10110.0%
Held by funds47.7%47.3%+0.3 pts
New / increased11 / 1319 / 19−36.8%
Reduced / sold out10 / 63 / 6+77.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RNTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RNTX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$75K2 buys · 2 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $75K between Apr 30 and May 27.
2026-04 bought $25K2026-05 bought $50KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
May 27Rickenbach Josef H VonDirectorBuy47,060$1.05$50K
Apr 30James Brian WindsorSee RemarksBuy25,000$1.00$25K
Nov 14, 2025Voss Value Master Fund, LP10% ownerBuy104,183$1.22$127K
Oct 28, 2025Voss Value-Oriented Special Situations Fund, LP10% ownerBuy306,050$1.38$423K
Dec 5, 2024James Brian WindsorPresident and CEOBuy400$2.24$898
Every insider buy and sale for RNTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RNTX insider trades →

From SEC Form 4 filings by RNTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNTX is in one of them and how their past RNTX trades turned out.

RNTX in the AI portfolios
Loading…

RNTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RNTX in an article yet. Here's the latest on the wider market.

RNTX in the news

About Rein Therapeutics

Rein Therapeutics is a biopharmaceutical company based in Austin, Texas, that develops treatments for rare lung diseases with few effective options. Its lead candidate, LTI-03, is an inhaled peptide being studied for idiopathic pulmonary fibrosis, a progressive lung disease. The company has paused work on its other candidates while it focuses on LTI-03. Its target patients are people living with lung fibrosis and related conditions.

Headquarters
Austin, TX